TABLE OF CONTENTS
1 INTRODUCTION 24
1.1 OBJECTIVES OF THE STUDY 24
1.2 MARKET DEFINITION 24
1.3 OVERVIEW OF NORTH AMERICA COLORECTAL SURGICAL DEVICES MARKET 24
1.4 LIMITATIONS 25
1.5 MARKETS COVERED 25
2 MARKET SEGMENTATION 27
2.1 MARKETS COVERED 27
2.2 GEOGRAPHICAL SCOPE 28
2.3 YEARS CONSIDERED FOR THE STUDY 29
2.4 CURRENCY AND PRICING 29
2.5 DBMR TRIPOD DATA VALIDATION MODEL 30
2.6 MULTIVARIATE MODELLING 33
2.7 PRODUCT TYPE LIFELINE CURVE 33
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 34
2.9 DBMR MARKET POSITION GRID 35
2.10 MARKET APPLICATION COVERAGE GRID 36
2.11 VENDOR SHARE ANALYSIS 37
2.12 SECONDARY SOURCES 38
2.13 ASSUMPTIONS 38
3 EXECUTIVE SUMMARY 39
4 PREMIUM INSIGHTS 42
4.1 PESTEL ANALYSIS 43
4.2 PORTERS FIVE FORCES 44
5 INDUSTRIAL INSIGHTS: 45
CONCLUSION: 45
6 NORTH AMERICA COLORECTAL SURGICAL DEVICES MARKET: REGULATIONS 46
6.1 REGULATION IN U.S 46
6.2 REGULATION IN EUROPE 47
6.3 REGULATION IN CANADA 47
6.4 REGULATION IN SOUTH AFRICA 48

7 MARKET OVERVIEW 49
7.1 DRIVERS 51
7.1.1 INCREASE IN GERIATRIC POPULATION 51
7.1.2 RISE IN NUMBER OF PATIENTS SUFFERING FROM DIVERTICULITIS AND ULCERATIVE COLITIS 51
7.1.3 INCREASE IN HEALTHCARE EXPENDITURE 52
7.1.4 RISE IN PREVALENCE OF COLORECTAL CANCER 53
7.2 RESTRAINTS 54
7.2.1 HIGH COST OF COLORECTAL SURGERY DEVICES 54
7.2.2 STRICT REGULATIONS 54
7.3 OPPORTUNITIES 55
7.3.1 STRATEGIC INITIATIVES TAKEN BY MARKET PLAYERS AND GOVERNMENT 55
7.3.2 INCREASE IN MINIMAL INVASIVE SURGERY PROCEDURE 55
7.3.3 RISING DISPOSABLE INCOME 56
7.4 CHALLENGES 56
7.4.1 COMPLICATIONS ASSOCIATED WITH PROCEDURE 56
1.4.1 SHORTAGE OF SKILLED PERSONNEL 57
8 NORTH AMERICA COLORECTAL SURGICAL DEVICES MARKET, BY PRODUCT TYPE 58
8.1 OVERVIEW 59
8.2 ENDOSCOPE 62
8.2.1 LAPAROSCOPE 63
8.2.2 COLONSCOPE 63
8.3 ELECTROSURGERY 63
8.3.1 INSTRUMENTS 64
8.3.2 ACCESSORIES 64
8.4 HANDHELD INSTRUMENTS 64
8.4.1 SCISSORS 65
8.4.2 FORCEPS 65
8.4.3 OTHERS 65
8.5 SEALING DEVICES 66
8.6 SURGICAL STAPLING DEVICES 67
8.7 ACCESSORIES 68
9 NORTH AMERICA COLORECTAL SURGICAL DEVICES MARKET, BY INDICATION 69
9.1 OVERVIEW 70
9.2 COLORECTAL CANCER 73
9.3 DIVERTICULITIS 74
9.4 ULCERATIVE COLITIS 75
9.5 CROHN'S DISEASE 76
9.6 OTHERS 77
10 NORTH AMERICA COLORECTAL SURGICAL DEVICES MARKET, BY END USER 78
10.1 OVERVIEW 79
10.2 SURGICAL CENTERS 82
10.3 HOSPITALS 83
10.4 CLINICS 84
10.5 OTHERS 85
11 NORTH AMERICA COLORECTAL SURGICAL DEVICES MARKET, BY REGION 86
11.1 NORTH AMERICA 87
11.1.1 U.S. 93
11.1.2 CANADA 95
11.1.3 MEXICO 97
12 NORTH AMERICA COLORECTAL SURGICAL DEVICES MARKET: COMPANY LANDSCAPE 99
12.1 COMPANY SHARE ANALYSIS: NORTH AMERICA 99
13 COMPANY PROFILE 100
13.1 MEDTRONIC 100
13.1.1 COMPANY SNAPSHOT 100
13.1.2 REVENUE ANALYSIS 101
13.1.3 COMPANY SHARE ANALYSIS 101
13.1.4 PRODUCT PORTFOLIO 101
13.1.5 RECENT DEVELOPMENT 102
13.1.5.1 PRODUCT LAUNCH 102
13.2 STRYKER 103
13.2.1 COMPANY SNAPSHOT 103
13.2.2 REVENUE ANALYSIS 103
13.2.3 COMPANY SHARE ANALYSIS 104
13.2.4 PRODUCT PORTFOLIO 104
13.2.5 RECENT DEVELOPMENTS 105
13.2.5.1 ACQUISITION 105
13.3 JOHNSON & JOHNSON SERVICES, INC 106
13.3.1 COMPANY SNAPSHOT 106
13.3.2 REVENUE ANALYSIS 106
13.3.3 COMPANY SHARE ANALYSIS 107
13.3.4 PRODUCT PORTFOLIO 107
13.3.5 RECENT DEVELOPMENTS 107
13.3.5.1 FDA CLEARANCE 107
13.3.5.2 STUDY RESULTS 107
13.4 BOSTON SCIENTIFIC CORPORATION 109
13.4.1 COMPANY SNAPSHOT 109
13.4.2 REVENUE ANALYSIS 109
13.4.3 COMPANY SHARE ANALYSIS 110
13.4.4 PRODUCT PORTFOLIO 110
13.4.5 RECENT DEVELOPMENTS 110
13.4.5.1 PRODUCT LAUNCH 110
13.4.5.2 AGREEMENT 111
13.5 KARL STORZ SE & CO. KG 112
13.5.1 COMPANY SNAPSHOT 112
13.5.2 COMPANY SHARE ANALYSIS 112
13.5.3 PRODUCT PORTFOLIO 113
13.5.4 RECENT DEVELOPMENTS 113
13.5.4.1 CONTRACT 113
13.5.4.2 INVESTMENT 114
13.6 BD 115
13.6.1 COMPANY SNAPSHOT 115
13.6.2 REVENUE ANALYSIS 115
13.6.3 PRODUCT PORTFOLIO 116
13.6.4 RECENT DEVELOPMENT 116
13.6.4.1 ACQUISITION 116
13.7 BIPAD SURGICAL, INC 117
13.7.1 COMPANY SNAPSHOT 117
13.7.2 PRODUCT PORTFOLIO 117
13.7.3 RECENT DEVELOPMENT 117
13.7.3.1 FDA APPROVAL 117
13.8 CARDINAL HEALTH 118
13.8.1 COMPANY SNAPSHOT 118
13.8.2 REVENUE ANALYSIS 118
13.8.3 PRODUCT PORTFOLIO 119
13.8.4 RECENT DEVELOPMENTS 119
13.8.4.1 NEW DISTRIBUTION CENTER 119
13.8.4.2 NEW DISTRIBUTION CENTER 119
13.9 COOK GROUP 120
13.9.1 COMPANY SNAPSHOT 120
13.9.2 PRODUCT PORTFOLIO 120
13.9.3 RECENT DEVELOPMENTS 121
13.9.3.1 ISO CERTIFICATION 121
13.9.3.2 INVESTMENT 121
13.10 CONMED CORPORATION 122
13.10.1 COMPANY SNAPSHOT 122
13.10.2 REVENUE ANALYSIS 122
13.10.3 PRODUCT PORTFOLIO 123
13.10.4 RECENT DEVELOPMENT 123
13.10.4.1 CONFERENCE 123
13.11 HALLMARK SURGICAL 124
13.11.1 COMPANY SNAPSHOT 124
13.11.2 PRODUCT PORTFOLIO 124
13.11.3 RECENT DEVELOPMENT 124
13.12 HEBSON 125
13.12.1 COMPANY SNAPSHOT 125
13.12.2 PRODUCT PORTFOLIO 125
13.12.3 RECENT DEVELOPMENT 125
13.13 OLYMPUS CORPORATION 126
13.13.1 COMPANY SNAPSHOT 126
13.13.2 REVENUE ANALYSIS 126
13.13.3 PRODUCT PORTFOLIO 127
13.13.4 RECENT DEVELOPMENT 127
13.13.4.1 PRODUCT LAUNCH 127
13.14 OVESCO ENDOSCOPY AG 128
13.14.1 COMPANY SNAPSHOT 128
13.14.2 PRODUCT PORTFOLIO 128
13.14.3 RECENT DEVELOPMENT 128
13.14.3.1 MARKET APPROVAL 128
13.15 PENTAX MEDICAL 129
13.15.1 COMPANY SNAPSHOT 129
13.15.2 REVENUE ANALYSIS 129
13.15.3 PRODUCT PORTFOLIO 130
13.15.4 RECENT DEVELOPMENTS 130
13.15.4.1 JOINT VENTURE 130
13.16 RICHARD WOLF GMBH 131
13.16.1 COMPANY SNAPSHOT 131
13.16.2 PRODUCT PORTFOLIO 131
13.16.3 RECENT DEVELOPMENT 131
13.16.3.1 NEW SUBSIDIARY 131
13.17 SAFEHEAL 132
13.17.1 COMPANY SNAPSHOT 132
13.17.2 PRODUCT PORTFOLIO 132
13.17.3 RECENT DEVELOPMENT 132
13.17.3.1 PARTNERSHIP 132
13.18 SMITH + NEPHEW 133
13.18.1 COMPANY SNAPSHOT 133
13.18.2 REVENUE ANALYSIS 133
13.18.3 PRODUCT PORTFOLIO 134
13.18.4 RECENT DEVELOPMENT 134
13.18.4.1 FDA APPROVAL 134
13.19 SUMMIT HILL LABORATORIES 135
13.19.1 COMPANY SNAPSHOT 135
13.19.2 PRODUCT PORTFOLIO 135
13.19.3 RECENT DEVELOPMENT 135
13.20 SYMMETRY SURGICAL, INC 136
13.20.1 COMPANY SNAPSHOT 136
13.20.2 PRODUCT PORTFOLIO 136
13.20.3 RECENT DEVELOPMENTS 137
13.20.3.1 ACQUISITION 137
13.21 TELEFLEX INCORPORATED 138
13.21.1 COMPANY SNAPSHOT 138
13.21.2 REVENUE ANALYSIS 138
13.21.3 PRODUCT PORTFOLIO 139
13.21.4 RECENT DEVELOPMENT 139
13.21.4.1 CONFERENCE 139
13.22 THE COOPER COMPANIES INC. 140
13.22.1 COMPANY SNAPSHOT 140
13.22.2 REVENUE ANALYSIS 140
13.22.3 PRODUCT PORTFOLIO 141
13.22.4 RECENT DEVELOPMENTS 141
13.22.4.1 ACQUISITION 141
13.23 W. L. GORE & ASSOCIATES, INC 142
13.23.1 COMPANY SNAPSHOT 142
13.23.2 PRODUCT PORTFOLIO 142
13.23.3 RECENT DEVELOPMENT 142
14 QUESTIONNAIRE 143
15 RELATED REPORTS 145

Menu 2

Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam.